Tatsis Ourania's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 18, 2026
- Accession no.
- 0000875320-26-000076
- Filed
- Feb 18, 2026
- Trade date
- Feb 13, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $750.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tatsis OuraniaCIK 0001789815 | Officer (EVP, Chief Reg. & Quality Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Common Stock | FTax withholdingDisposed | −3,804 | $487.76 | −$1,855,439.04 | 47,632 | Direct | |
| Feb 13, 2026 | Common Stock | SSaleDisposed | −1,500 | $499.99 | −$749,985 | 46,132 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.